Article Text

PDF
Risk of lymphoproliferative cancer among patients with severe rheumatoid arthritis, 1996–2002
  1. L J Herrinton1,
  2. L Liu1,
  3. S Shoor2,
  4. D Mines3
  1. 1
    Division of Research, Kaiser Permanente Northern California, Oakland, California, USA
  2. 2
    Department of Rheumatology, Kaiser Medical Center, Santa Clara, California, USA
  3. 3
    Global Safety Surveillance and Epidemiology, Wyeth Research, Collegeville, Pennyslvania, USA
  1. L J Herrinton, Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, 94612, USA; Lisa.Herrinton{at}kp.org

Statistics from Altmetric.com

Patients with rheumatoid arthritis (RA) are at increased risk of lymphoma,14 and anti-tumour necrosis factor (TNF) agents may further increase this risk.5 6 We conducted a retrospective cohort study of this question using the computerised data of Kaiser Permanente (KP; http://www.kaiserpermanente.org/). We defined a “severe RA cohort” of potential candidates for anti-TNF therapy as those aged 18 years and older from 1996–2002 who received at least two diagnoses of RA and were prescribed a disease-modifying antirheumatic drug (DMARD) after receiving methotrexate (n = 3982). Patients who had a previous history of anti-TNF agent were excluded. Follow-up began with the prescription of the first DMARD after methotrexate …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.